High drug price associated with decreased treatment retention for patients with chronic liver disease

Researchers from the University of Minnesota Medical School and College of Pharmacy have found that high costs for hepatic encephalopathy treatment in patients with end-stage liver disease were associated with decreased treatment retention for patients. The study results were recently published in Hepatology Communications. Hepatic encephalopathy is the loss of brain function that occurs in people with severe liver disease. The […]

Mulpleta approved in China to treatthrombocytopenia in adult patients with chronic liver disease – Eddingpharm

Shionogi announced that its Chinese license partner Eddingpharm has won regulatory approval for its thrombopoietin receptor agonist Mulpleta (lusutrombopag) in China. The drug was approved for the treatment of thrombocytopenia in adult patients with chronic liver disease (CLD) who are scheduled to undergo an elective invasive procedure. Originated by Shionogi, Mulpleta is a small molecule agonist of the human thrombopoietin […]